Drug discovery and development – Page 11
-
ResearchLeft-handed nanoparticles are far better vaccine adjuvants than their mirror images
Chiral gold nanoparticles shown for the first time to elicit differing immune responses in cells and live mice
-
NewsExplainer: How do the Covid vaccines measure up against each other and omicron?
Looking at how the evidence stacks up for vaccines against variants and how their performance holds up over time
-
OpinionLetters: February 2022
Readers investigate June Lindsey’s legacy, question policy and celebrate vaccination
-
OpinionThe shadow of drug resistance
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?
-
OpinionThe law of conservation of data
AI and machine learning are useful and powerful, but they need high quality data inputs that aren’t available yet for drug discovery
-
OpinionWhen regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
WebinarUsing flow chemistry to give early drug discovery processes a boost
Discover how pioneering modular flow chemistry technologies can unlock the potential for discovery chemists to accelerate research
-
BusinessPfizer sues former employee for alleged trade secret theft
Chun Xiao Li downloaded thousands of confidential documents before resigning
-
BusinessCovid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
-
ResearchGallium helps sneak antibiotic payload into bacterial cells
Compound is more potent than parent drug ciprofloxacin against Staphylococcus aureus
-
FeaturemRNA vaccines for Covid and beyond
Already hailed as a miracle, the new vaccine technology could protect us from other diseases, Clare Sansom finds
-
ArticleFacilitating the future
A view from the top at Johnson Matthey on the future of drug development
-
OpinionA vaccine for all seasons?
Phase 1 clinical trials have begun on a candidate that could work against a wide range of flu viruses
-
NewsFirst malaria vaccine approved as hopes raised for new, better ones
Mosquirix prevents just 30% of severe malaria cases in young children prompting a guarded welcome
-
ArticleAstraZeneca explores new frontiers through academic collaborations
The important of partnerships between industry and academia to drive innovation
-
BusinessNew antiviral impresses against Covid-19
Merck & Co and Ridgeback’s molnupiravir reduces risk of hospitalisation and death, and may work against other coronaviruses
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
NewsChemistry Nobel predictions range from free-radical chemistry to MOFs
Data-crunching goes up against gut feeling as the chemistry community weighs in on their favourites for the world’s top chemistry prize
-
ResearchProgrammable peptoid template for disrupting protein–protein interactions inside cells
System optimises residues involved in binding target independently from those that promote membrane permeability